Pediatric Zylet Safety and Efficacy Study

Inclusion Criteria: * Child, 0 to 6 years of age, any sex and race * Subject must have a clinical diagnosis of lid inflammation (e.g. Chalazion/Hordeolum) in at least one eye. If both eyes are diagnosed with lid inflammation, both eyes will be treated * In good health (no current or past relevant medical history), based on the judgment of the investigator * Parent/guardian is able and willing to follow instructions and provide informed consent Exclusion Criteria: * Known hypersensitivity to corticosteroids, loteprednol etabonate, or any component of the study medication * Known hypersensitivity to aminoglycosides, tobramycin, or any component of the study medication * Use of concurrent ocular therapy with non-steroidal anti-inflammatory agent (NSAID), mast cell stabilizer, antihistamine, or decongestant within 48 hours before and during the study * Use of oral or topical ophthalmic corticosteroids (other than study medication) within 48 hours before and during the study * Use of systemic antibiotics within 72 hours before and during the 14 day study medication treatment duration * Use of topical ophthalmic antibiotics (other than the study medication) within 72 hours before and during the study * History of ocular surgery, including laser procedures, within the past six months * Anticipation that surgical intervention for lid inflammation will be required prior to completion of the study * Subjects with suspected vernal conjunctivitis, glaucoma of any kind, viral or bacter…